Member Info for Rocket79

Ignore derampers trying to get in cheaper... as has been mentioned figures will gmalsi be updated as the collaboration progresses.

Presentation is up - look at those potentials

Exceeding 20% target of last year

Estimated revenue potential in NY $754 mill

Texas - $1.3 billion

Florida - $921 mil

https://investors.renalytix.com/presentations/.

And the placing was over subscribed. Hold and these will be alot higher in coming days.

RNS was good and will be revisedas collaboration progresses. Directors bought in @ 9.5p. Strong Buy. Certain Directors are to subscribe for approximately 2.84 million new Ordinary Shares in the Placing, raising approximately £270,000 in aggregate, before expenses.

Short term investors who dont understand markets selling out. Giving us an opportunity.These will rise from here. Educated traders buying in as can see values. Good luck all

Nows the time to be in as once we start seeing results these will be 50p ±

Ignore derampers trying to get in cheaper... as has been mentioned figures will gmalsi be updated as the collaboration progresses.

Presentation is up - look at those potentials

Exceeding 20% target of last year

Estimated revenue potential in NY $754 mill

Texas - $1.3 billion

Florida - $921 mil

https://investors.renalytix.com/presentations/.

Presentation is up - look at those potentials

Exceeding 20% target of last year

Estimated revenue potential in NY $754 mill

Texas - $1.3 billion

Florida - $921 mil

https://investors.renalytix.com/presentations/.

These will rerate

The Board of Directors are currently considering the long-term positive impact of the Tempus collaboration and the Company will provide further updates regarding forward revenue guidance as appropriate, as the two parties execute implementation into hospital systems and other healthcare providers.

Boooom time?

Presentation is up - look at those potentials

Exceeding 20% target of last year

Estimated revenue potential in NY $754 mill

Texas - $1.3 billion

Florida - $921 mil

https://investors.renalytix.com/presentations/.

Reate today this will be hitting 30p very soon...

Revised forward guidance on expected long-term increase in revenue

No funding was required and they were forecast to break even 2027. However in comes the collaboration with Tempus AI who will now supercharge revenues.... funds raised were for this collaboration. Strong Buy

No they could not do that. Althpugh i agree the raise will allow Renalytix to turbo charge revenues with thecollaboration. Bargain at this price.

Now funds raised to supercharge collaboration revenues this is going to rerate.

Now why would the CEO tweet the below?? Tempus is a multi billion dollar company... They know they can make some serous money with the collaboration with Renalytix. Takeover coming imo

Ryan FukushimaRyan Fukushima COO at Tempus AI | Cofounder of Pathos AIThe brutal truth about chronic kidney disease:

• 15 million Americans have diabetic kidney disease • 90% patients don't even know they have it

• Medicare spends $130 billion annually cleaning up the aftermathThis isn't just market opportunity. It's a silent epidemic.

[Enter Renalytix] FDA-approved test. Medicare reimbursed. Predicts kidney disease progression in diabetic patients.

But here's what stopped me in my tracks about them:

They weren't pitching their algorithm's accuracy. They were obsessing over physician workflow integration.

That's when I knew we had to work together.

Our partner just hit a 52 week high, current mcap of £16 billion dollars.... now why would they partner with Renalytix? They are in to make some significant cash...

Funds raised and oversubscribed. Onwards and upwards.. Strong Buy

James McCullough, CEO of Renalytix commented: "The successful result of this fundraising provides important resources to support our growth and new collaboration with Tempus AI. Together we can expand advanced precision medicine testing to directly into the existing clinical work flow of the some 250,000 U.S. primary care physicians caring for one of the largest chronic diseases populations today."

Now funds raised to supercharge collaboration revenues this is going to rerate.

Now why would the CEO tweet the below?? Tempus is a multi billion dollar company... They know they can make some serous money with the collaboration with Renalytix. Takeover coming imo

Ryan FukushimaRyan Fukushima COO at Tempus AI | Cofounder of Pathos AIThe brutal truth about chronic kidney disease:

• 15 million Americans have diabetic kidney disease • 90% patients don't even know they have it

• Medicare spends $130 billion annually cleaning up the aftermathThis isn't just market opportunity. It's a silent epidemic.

[Enter Renalytix] FDA-approved test. Medicare reimbursed. Predicts kidney disease progression in diabetic patients.

But here's what stopped me in my tracks about them:

They weren't pitching their algorithm's accuracy. They were obsessing over physician workflow integration.

That's when I knew we had to work together.

Those buying in now will be hansomly rewarded imo. These are incredible value with the collaboration news not factored in at all. The collaboration is going to super charge earnings imo

No brainer buying in a this price...

The fundraise aims to fuel Renalytix's growth strategy, particularly the wider adoption of kidneyintelX.dkd. This test is currently the only FDA-approved and Medicare-reimbursed prognostic tool for early-stage risk assessment in chronic kidney disease.

Funds are going to be used for the collaboration. This is excellent news.

Renalytix have just went into a collaboration with a multi billion dollar company. They can obviously see values here.

The partnership with Tempus is a game-changer for Renalytix because it provides a massive, pre-built distribution network for its KidneyIntelX.dkd test. This collaboration gives Renalytix immediate access to Tempus's network of over 2,000 healthcare institutions, eliminating the need to build a costly sales team.

​By integrating the test into Tempus's AI platform, which is already used by doctors, the partnership simplifies the ordering process and accelerates market adoption. This strategic move is expected to significantly boost the volume of tests sold, paving the way for substantial revenue growth and long-term commercial success for Renalytix

They did not required funds to break even in 2027, however the collaboration with Tempus AI was not known about then. This is a significant milestone and the funds will be used to accelerate this. Great news.